GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Integrated Biopharma Inc (OTCPK:INBP) » Definitions » Beneish M-Score

INBP (Integrated Biopharma) Beneish M-Score : -2.46 (As of Dec. 15, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Integrated Biopharma Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.46 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Integrated Biopharma's Beneish M-Score or its related term are showing as below:

INBP' s Beneish M-Score Range Over the Past 10 Years
Min: -2.98   Med: -2.1   Max: -0.79
Current: -2.46

During the past 13 years, the highest Beneish M-Score of Integrated Biopharma was -0.79. The lowest was -2.98. And the median was -2.10.


Integrated Biopharma Beneish M-Score Historical Data

The historical data trend for Integrated Biopharma's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integrated Biopharma Beneish M-Score Chart

Integrated Biopharma Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.05 -1.54 -2.24 -2.58 -2.61

Integrated Biopharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.44 -2.44 -2.37 -2.61 -2.46

Competitive Comparison of Integrated Biopharma's Beneish M-Score

For the Packaged Foods subindustry, Integrated Biopharma's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Integrated Biopharma's Beneish M-Score Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Integrated Biopharma's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Integrated Biopharma's Beneish M-Score falls into.



Integrated Biopharma Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Integrated Biopharma for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.056+0.528 * 0.8767+0.404 * 0.9504+0.892 * 0.9953+0.115 * 0.8355
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9444+4.679 * 0.0055-0.327 * 0.8702
=-2.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was $4.39 Mil.
Revenue was 13.617 + 12.746 + 13.147 + 11.509 = $51.02 Mil.
Gross Profit was 1.371 + 1.284 + 1.248 + 0.52 = $4.42 Mil.
Total Current Assets was $18.31 Mil.
Total Assets was $26.18 Mil.
Property, Plant and Equipment(Net PPE) was $3.41 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.24 Mil.
Selling, General, & Admin. Expense(SGA) was $3.63 Mil.
Total Current Liabilities was $6.03 Mil.
Long-Term Debt & Capital Lease Obligation was $0.60 Mil.
Net Income was 0.259 + 0.268 + 0.285 + -0.382 = $0.43 Mil.
Non Operating Income was 0 + 0 + 0.001 + -0.002 = $-0.00 Mil.
Cash Flow from Operations was 0.657 + -0.186 + 1.13 + -1.314 = $0.29 Mil.
Total Receivables was $4.17 Mil.
Revenue was 12.915 + 12.994 + 13.098 + 12.254 = $51.26 Mil.
Gross Profit was 0.832 + 0.986 + 1.008 + 1.07 = $3.90 Mil.
Total Current Assets was $17.76 Mil.
Total Assets was $26.64 Mil.
Property, Plant and Equipment(Net PPE) was $4.11 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.18 Mil.
Selling, General, & Admin. Expense(SGA) was $3.86 Mil.
Total Current Liabilities was $6.20 Mil.
Long-Term Debt & Capital Lease Obligation was $1.56 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(4.385 / 51.019) / (4.172 / 51.261)
=0.085948 / 0.081387
=1.056

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(3.896 / 51.261) / (4.423 / 51.019)
=0.076003 / 0.086693
=0.8767

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (18.312 + 3.411) / 26.183) / (1 - (17.759 + 4.108) / 26.642)
=0.17034 / 0.179228
=0.9504

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=51.019 / 51.261
=0.9953

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.18 / (1.18 + 4.108)) / (1.243 / (1.243 + 3.411))
=0.223147 / 0.267082
=0.8355

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(3.628 / 51.019) / (3.86 / 51.261)
=0.071111 / 0.075301
=0.9444

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.604 + 6.029) / 26.183) / ((1.559 + 6.197) / 26.642)
=0.253332 / 0.291119
=0.8702

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(0.43 - -0.001 - 0.287) / 26.183
=0.0055

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Integrated Biopharma has a M-score of -2.46 suggests that the company is unlikely to be a manipulator.


Integrated Biopharma Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Integrated Biopharma's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Integrated Biopharma Business Description

Traded in Other Exchanges
N/A
Address
225 Long Avenue, Building 15, Hillside, NJ, USA, 07205
Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments; Contract Manufacturing and Other Nutraceutical Businesses. Key revenue is generated from Contract Manufacturing segment which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers.
Executives
Damon Desantis director 2424 N FEDERAL HIGHWAY, SUITE 208, BOCA RATON FL 33431
William H. Milmoe director, 10 percent owner 3299 N.W. 2ND AVENUE, BOCA RATON FL 33431
Joseph Laplaca director 72 EUGENE DRIVE, MONTVILLE NJ 07045
E Gerald Kay director, 10 percent owner, officer: Chairman and CEO C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Bradley J Hoecker director STONINGTON PARTNERS, INC., 540 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Jeffrey R Leach director, officer: President and CEO
Glenn Chang director C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Vidadi Yusibov director C/O IBIOPHARMA, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Cd Financial, Llc 10 percent owner 3299 N.W. 2ND AVENUE, BOCA RATON FL 33431
Kay Riva director, officer: Vice President C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Christina Kay director, officer: Vive President C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Robert Canarick director C/O INTEGRATED BIOPHARMA, INC., 201 ROUTE 22, HILLSIDE NJ 07205
Robert Kay director C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Dina Masi officer: Chief Financial Officer 14 LEXINGTON WAY, LONG VALLEY NJ 07853
Carl Desantis director, 10 percent owner C/O CDS INTERNATIONAL HOLDINGS, 3299 NW SECOND AVE, BOCA RATON FL 33431